Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 9/20 | 0.45 |
| ▸ | F10 | P00742 | 9/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394499 | 1.00 | HSD11B1 (0.68) | HSD11B1AKR1C3AKR1C1NPC1MAPT | |
| SCHEMBL176859 | 1.00 | HSD11B1 (0.68) | HSD11B1AKR1C3AKR1C1NPC1MAPT | |
| SCHEMBL394500 | 1.00 | HSD11B1 (0.68) | HSD11B1AKR1C3AKR1C1NPC1MAPT | |
| SCHEMBL257392 | 1.00 | HSD11B1 (0.68) | HSD11B1AKR1C3AKR1C1NPC1MAPT | |
| SCHEMBL182196 | 0.98 | HSD11B1 (0.70) | HSD11B1AKR1C3AKR1C1NPC1MAPT | |
| SCHEMBL182195 | 0.98 | HSD11B1 (0.70) | HSD11B1AKR1C3AKR1C1NPC1MAPT | |
| SCHEMBL2717308 | 0.98 | HSD11B1 (0.70) | HSD11B1AKR1C3AKR1C1NPC1MAPT | |
| SCHEMBL1524445 | 0.94 | HSD11B1 (0.76) | HSD11B1AKR1C3AKR1C1NPC1MAPT | |
| SCHEMBL643540 | 0.94 | HSD11B1 (0.76) | HSD11B1AKR1C3AKR1C1NPC1MAPT | |
| SCHEMBL643539 | 0.94 | HSD11B1 (0.76) | HSD11B1AKR1C3AKR1C1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378117-B2 | 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8378096-B2 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| EP-2139328-A2 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2010-01-06 | — | — | EP | disclosed |
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-06 | — | — | US | disclosed |
| CN-101312726-A | Hexahydro cyclooctyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-26 | — | — | CN | disclosed |
| WO-2008115705-A2 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1937259-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | disclosed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | disclosed |
| WO-2007038036-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-05 | — | — | WO | disclosed |
| US-5639918-A | Intermediate compounds useful in the preparation of fungicidal compositions containing (benzylidene)-azolylmethyclycloalkane | RHONE-POULENC AGROCHIMIE (FR) | 1997-06-17 | — | — | US | disclosed |
| CN-1031971-C | (Benzylidene)-azolylmethylcycloalkane and use as fungicide | RHONE POULENC AGROCHIMIE (FR) | 1996-06-12 | — | — | CN | disclosed |
| EP-0378953-B1 | Benzylidene azolyl methyl cycloalkane and its use as a fungicide | RHONE POULENC AGROCHIMIE (FR) | 1996-06-05 | — | — | EP | disclosed |
| US-5380743-A | Fungicidal compositions containing (benzylidene)-azolymethylcycloalkane | RHONE-POULENC AGROCHIMIE (FR) | 1995-01-10 | — | — | US | disclosed |
| US-5256683-A | Plant protective agent 1H-1,2,4-triazolylmethylcycloalkane or -alkene benzylidene | RHONE-POULENC AGROCHIMIE (FR) | 1993-10-26 | — | — | US | disclosed |
| EP-0378953-A1 | Benzylidene azolyl methyl cycloalkane and its use as a fungicide | RHONE-POULENC AGROCHIMIE (FR) | 1990-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | CNR2, CNR1, FAAH | HSD11B1 725/4885AKR1C3 1005/4885AKR1C1 1656/4885 |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | CNR2, CNR1, FAAH | HSD11B1 725/4885AKR1C3 1005/4885AKR1C1 1656/4885 |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | CNR2, CNR1, FAAH | HSD11B1 725/4885AKR1C3 1005/4885AKR1C1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.